Aisling Capital Management LP — 13F Holdings & Portfolio
CIK 1766721 · latest 13F-HR filed 2026-08-13
Aisling Capital Management LP manages $471.6M in 13F-reported U.S. long-equity assets across 14 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BBIO (72.48%), GLUE (7.98%), SNDX (6.10%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 0, added to 8, and trimmed 4.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$471.6M
Long-equity book
14
Distinct positions
2026-06-30
Filed 2026-08-13
+1 / −0 / ↑8 / ↓4
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Share-count changes vs the prior 13F.
Top Adds (vs prior quarter)
- COMPASS PATHWAYS PLC$12.3M +155.9%
- MONTE ROSA THERAPEUTICS INC$12.1M +47.1%
- BICARA THERAPEUTICS INC$5.6M +49.3%
- UROGEN PHARMA LTD$2.0M +104.7%
- ACLARIS THERAPEUTICS INC$669.1K +41.1%
Top Trims
- BRIDGEBIO PHARMA INC-$36.1M -9.6%
- SYNDAX PHARMACEUTICALS INC-$2.0M -6.4%
- BRIDGEBIO ONCOLOGY THERAPEUT-$1.4M -14.9%
- EUPRAXIA PHARMACEUTICALS INC-$204.8K -8.7%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $341.8M | 72.48% | 4,589,611 | SH |
| 2 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $37.6M | 7.98% | 1,555,664 | SH |
| 3 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $28.8M | 6.10% | 1,316,806 | SH |
| 4 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $20.3M | 4.30% | 1,432,336 | SH |
| 5 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $16.9M | 3.58% | 568,919 | SH |
| 6 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $7.8M | 1.64% | 1,018,018 | SH |
| 7 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $4.2M | 0.90% | 77,031 | SH |
| 8 | UROGEN PHARMA LTD | URGN | M96088105 | $4.0M | 0.84% | 108,000 | SH |
| 9 | BIOMEA FUSION INC | BMEA | 09077A106 | $3.0M | 0.64% | 2,048,757 | SH |
| 10 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $2.3M | 0.49% | 434,455 | SH |
| 11 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $2.1M | 0.46% | 325,000 | SH |
| 12 | VTV THERAPEUTICS INC | VTVT | 918385204 | $1.9M | 0.40% | 50,000 | SH |
| 13 | MARKER THERAPEUTICS INC | MRKR | 57055L206 | $478.3K | 0.10% | 325,370 | SH |
| 14 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $404.0K | 0.09% | 88,607 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $471.6M | 14 | 0001766721-26-000003 |
| 2026-03-31 | 2026-05-05 | $476.3M | 13 | 0001766721-26-000002 |
| 2025-12-31 | 2026-02-10 | $478.9M | 13 | 0001766721-26-000001 |
NEW YORK, NY 10017